Alopexx, Inc. (ALPX)

Alopexx will go public soon, but the exact IPO date is still unknown.
Stock Price: Pending
IPO price not available yet
Chart not available yet
Data will show when the stock starts trading.
Market Capn/a
Revenue (ttm)n/a
Net Income (ttm)-956,954
Shares Outn/a
EPS (ttm)n/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Openn/a
Previous Closen/a
Day's Rangen/a
52-Week Rangen/a
Betan/a
Analystsn/a
Price Targetn/a
Earnings Daten/a

About ALPX

Alopexx is a clinical stage biotechnology company developing novel immune therapeutics for the prevention, treatment and mitigation of bacterial, fungal, and parasitic infections that express the antigenic target poly N-acetyl glucosamine (PNAG). To date over 75 separate pathogens have been found to express PNAG. While the ultimate decision on the safety and efficacy of our therapeutics will be determined by the FDA and other health authorities, it is our management’s assessment that the broad-spectrum potential of our therapeutics will allow...

IndustryHealth Care
Founded2006
CEODaniel R. Vlock
CountryUnited States
Stock ExchangeNASDAQ
Ticker SymbolALPX
Full Company Profile

Financial Performance

Financial Statements

News

Alopexx IPO Registration Document (S-1)

Alopexx has filed to go public with an IPO on the NASDAQ.

1 month ago - SEC

Biopharma financings cut by a third, transactions track with 2019 and earlier

Financings in the first two months of 2022 amount to only a third of the money raised during the same timeframe of 2021 and the number of transactions is down by 56 percent.

2 months ago - BioWorld

Infectious disease biotech Alopexx files for a $17 million IPO

Alopexx, a Phase 2 biotech developing immune therapies for bacterial, fungal, and parasitic infections, filed on Monday with the SEC to raise up to $17 million in an initial public offering.

2 months ago - Renaissance Capital